Sphera Funds Management Ltd. Janux Therapeutics, Inc. Transaction History
Sphera Funds Management Ltd.
- $363 Million
- Q2 2025
A detailed history of Sphera Funds Management Ltd. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 85,840 shares of JANX stock, worth $1.95 Million. This represents 0.55% of its overall portfolio holdings.
Number of Shares
85,840
Previous 125,840
31.79%
Holding current value
$1.95 Million
Previous $3.4 Million
41.65%
% of portfolio
0.55%
Previous 0.89%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
55.9MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$254 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$101 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$66.3 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$57.3 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$53.2 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $945M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...